Intensity Therapeutics, Inc.
INTS
$6.31
-$0.18-2.82%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 4.79M | 5.02M | 5.37M | 6.09M | 6.40M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 12.04M | 12.87M | 15.24M | 16.59M | 16.73M |
| Operating Income | -12.04M | -12.87M | -15.24M | -16.59M | -16.73M |
| Income Before Tax | -11.74M | -12.58M | -15.01M | -16.27M | -16.26M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -11.74 | -12.58 | -15.01 | -16.27 | -16.26 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -11.74M | -12.58M | -15.01M | -16.27M | -16.26M |
| EBIT | -12.04M | -12.87M | -15.24M | -16.59M | -16.73M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -15.95 | -20.76 | -26.46 | -29.34 | -29.58 |
| Normalized Basic EPS | -9.97 | -12.98 | -16.54 | -18.34 | -18.49 |
| EPS Diluted | -15.95 | -20.76 | -26.46 | -29.34 | -29.58 |
| Normalized Diluted EPS | -9.97 | -12.98 | -16.54 | -18.34 | -18.49 |
| Average Basic Shares Outstanding | 3.66M | 2.49M | 2.28M | 2.23M | 2.20M |
| Average Diluted Shares Outstanding | 3.66M | 2.49M | 2.28M | 2.23M | 2.20M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |